Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Apatinib Mesylate
2. Rivoceranib
3. Rivoceranib Mesylate
4. Yn-968d1
5. Yn968d1
1. 811803-05-1
2. Rivoceranib
3. Apatinib Free Base
4. Yn968d1
5. N-(4-(1-cyanocyclopentyl)phenyl)-2-((pyridin-4-ylmethyl)amino)nicotinamide
6. N-[4-(1-cyanocyclopentyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide
7. 5s371k6132
8. N-(4-(1-cyanocyclopentyl)phenyl)-2-(pyridin-4-ylmethylamino)nicotinamide
9. 3-pyridinecarboxamide, N-(4-(1-cyanocyclopentyl)phenyl)-2-((4-pyridinylmethyl)amino)-
10. Unii-5s371k6132
11. Apatinib (in China)
12. Rivoceranib [inn]
13. Rivoceranib (usan/inn)
14. Rivoceranib [usan]
15. Rivoceranib [who-dd]
16. Gtpl7648
17. Schembl1814966
18. Chembl3186534
19. Apatinib Free Base; Yn-968d1
20. Dtxsid601024366
21. Amy21302
22. Bcp02840
23. Ex-a1794
24. Hy-13342a
25. Mfcd21648511
26. Nsc772886
27. Nsc799333
28. S5248
29. Zinc70466461
30. Akos024464453
31. Ccg-268625
32. Db14765
33. Ds-7455
34. Nsc-772886
35. Nsc-799333
36. Sb16590
37. N-[4-(1-cyanocyclopentyl)phenyl]-2-[(4-pyridinylmethyl)amino]-3-pyridinecarboxamide
38. Ncgc00249393-01
39. Ncgc00249393-08
40. Ac-27461
41. Ba175030
42. Da-35324
43. Cs-0003200
44. C76598
45. D11288
46. Ab01274807-01
47. Ab01274807_02
48. Q27262801
49. N-[4-(1-cyanocyclopentyl)phenyl]-2-[(4-pyridinylmethyl)amino]nicotinamide
50. N-(4-(1-cyanocyclopentyl)phenyl)-2-((pyridin-4-ylmethyl)amino)pyridine-3-carboxamide
| Molecular Weight | 397.5 g/mol |
|---|---|
| Molecular Formula | C24H23N5O |
| XLogP3 | 4.1 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 5 |
| Rotatable Bond Count | 6 |
| Exact Mass | 397.19026037 g/mol |
| Monoisotopic Mass | 397.19026037 g/mol |
| Topological Polar Surface Area | 90.7 Ų |
| Heavy Atom Count | 30 |
| Formal Charge | 0 |
| Complexity | 608 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Antineoplastic Agents
Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)
Protein Kinase Inhibitors
Agents that inhibit PROTEIN KINASES. (See all compounds classified as Protein Kinase Inhibitors.)
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATES SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
A Rivoceranib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Rivoceranib, including repackagers and relabelers. The FDA regulates Rivoceranib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Rivoceranib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Rivoceranib supplier is an individual or a company that provides Rivoceranib active pharmaceutical ingredient (API) or Rivoceranib finished formulations upon request. The Rivoceranib suppliers may include Rivoceranib API manufacturers, exporters, distributors and traders.
click here to find a list of Rivoceranib suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Rivoceranib DMF (Drug Master File) is a document detailing the whole manufacturing process of Rivoceranib active pharmaceutical ingredient (API) in detail. Different forms of Rivoceranib DMFs exist exist since differing nations have different regulations, such as Rivoceranib USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Rivoceranib DMF submitted to regulatory agencies in the US is known as a USDMF. Rivoceranib USDMF includes data on Rivoceranib's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Rivoceranib USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Rivoceranib suppliers with USDMF on PharmaCompass.
Rivoceranib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Rivoceranib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Rivoceranib GMP manufacturer or Rivoceranib GMP API supplier for your needs.
A Rivoceranib CoA (Certificate of Analysis) is a formal document that attests to Rivoceranib's compliance with Rivoceranib specifications and serves as a tool for batch-level quality control.
Rivoceranib CoA mostly includes findings from lab analyses of a specific batch. For each Rivoceranib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Rivoceranib may be tested according to a variety of international standards, such as European Pharmacopoeia (Rivoceranib EP), Rivoceranib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Rivoceranib USP).
LOOKING FOR A SUPPLIER?
